Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The pharmacologic profile of desloratadine: a review
Autore:
Henz, BM;
Indirizzi:
Humboldt Univ, Charite, Dept Dermatol & Allergy, Berlin, Germany Humboldt Univ Berlin Germany , Dept Dermatol & Allergy, Berlin, Germany
Titolo Testata:
ALLERGY
, volume: 56, anno: 2001, supplemento:, 65
pagine: 7 - 13
SICI:
0105-4538(2001)56:<7:TPPODA>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
TORSADES-DE-POINTES; INHIBITORY ACTIVITY; MAST-CELLS; LORATADINE; TERFENADINE; EXPRESSION; RELEASE; CARDIOTOXICITY; INFLAMMATION; MECHANISMS;
Keywords:
allergic rhinitis; antihistamine; cardiac safety; desloratadine; pharmacodynamics; pharmacokinetics; urticaria;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
44
Recensione:
Indirizzi per estratti:
Indirizzo: Henz, BM Humboldt Univ, Charite, Dept Dermatol & Allergy, Berlin, Germany Humboldt Univ Berlin Germany rmatol & Allergy, Berlin, Germany
Citazione:
B.M. Henz, "The pharmacologic profile of desloratadine: a review", ALLERGY, 56, 2001, pp. 7-13

Abstract

Desloratadine is a new agent for the treatment of diseases such as seasonal allergic rhinitis and chronic urticaria. The pharmacologic profile of desloratadine offers particular benefits in terms of histamine H-1-receptor binding potency and H-1 selectivity. Desloratadine has a half-life of 21-24 h, permitting once-daily dosing. No specific cautions are required with respect to administration in renal or hepatic failure, and food or grapefruit juice have no effect on the pharmacologic parameters. No clinically relevantracial or sex variations in the disposition of desloratadine have been noted. In combination with the cytochrome P450 inhibitors, ketoconazole and erythromycin, the AUC and C-max of desloratadine were increased to a small extent, but no clinically relevant drug accumulation occurred. With high-dosetreatment (45 mg/day for 10 days), no significant adverse events were observed, despite the sustained elevation of plasma desloratadine levels. Specifically, desloratadine had no effects on the corrected QT interval (QTc) when administered alone, at high dose, or in combination with ketoconazole orerythromycin. Preclinical studies also show that desloratadine does not interfere with HERG channels or cardiac conduction parameters even at high dose. Desloratadine is nonsedating and free of antimuscarinic/anticholinergiceffects in preclinical and clinical studies. Novel antiallergic and anti-inflammatory effects have also been noted with desloratadine, a fact which may be relevant to its clinical efficacy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 14:37:59